Overview
-

Kohjin Bio Co.,Ltd.

Kojin Bio is a Japan-based biotechnology company engaged in the development, manufacturing, and sale of cell culture media, bacterial culture media, and in vitro diagnostic pharmaceuticals, as well as contract cell processing services. The company focuses particularly on serum-free media for regenerative medicine applications, including proprietary KBM-series products for immune cells (T cells, NK cells), mesenchymal stem cells, neural stem cells, and vascular endothelial cells. Its competitive strengths lie in specialized formulation expertise for cell therapy and biopharmaceutical manufacturing applications, with operations spanning Japan, Hong Kong, and China.

Market Cap
¥3.92B
US$25.0M
EV
¥2.72B
US$17.3M
Stock¥767▼-0.90%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
4.9
x
LTM EV/EBIT
17.4
x
LTM PER
30.6
x
LTM PBR
0.7
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-71.8%pt
100
Oct 24, 25 – Oct 23, 26StockTOPIX
MC → EV Bridge
3.92BUS$25.0MMarket Cap1.84BUS$11.7M+ Debt2.38BUS$15.2M− Cash0.66BUS$4.22M− Inv. Sec.2.72BUS$17.3MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
3.95US$25.2M'22/34.74US$30.2M'23/34.77US$30.4M'24/35.21US$33.2M'25/34.94US$31.5M'26/3
EBITDA 5Y (¥B)
0.90US$5.71M'24/31.35US$8.62M'25/30.74US$4.70M'26/3
Net Income 5Y (¥B)
0.59US$3.75M'22/30.83US$5.29M'23/30.38US$2.45M'24/30.79US$5.06M'25/30.25US$1.60M'26/3
Capital Structure
76%
24%
EquityD/E 0.31xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
'22/30.41US$2.61M'23/32.21US$14.1M2.47US$15.8M'24/33.73US$23.8M2.39US$15.2M'25/33.15US$20.1M2.19US$14.0M'26/3
Shareholders
Top 10 hold 78.7%
1
Takahito NAKAMURA
43.20%
2
TAKA Corporation Co., Ltd.
8.20%
3
GOLDMAN SACHS INTERNATIONAL (Standing Proxy: Goldman Sachs Japan Co., Ltd.)
7.60%
4
Oriental Yeast Co., Ltd.
5.30%
5
BNY GCM CLIENT ACCOUNT JPRD AC ISG (FE-AC; Standing Proxy: MUFG Bank, Ltd.)
4.50%
6
Fujifilm Wako Pure Chemical Corporation
2.70%
7
Kohjin Bio Co.,Ltd. Employee Stock Ownership Association
2.30%
8
COSMO BIO COMPANY,LIMITED
2.00%
9
Tsunemi WATANABE
1.50%
10
Ieda Chemical Co., Ltd.
1.40%
Management
7 officers
Takahito NAKAMURA
Representative Director, Chairman
Apr 1973 Joined Marudai Food Co., Ltd. Apr 1981 Established Kojin Co., Ltd. (current company); assumed office as Representative Director, President Apr 2003 Established Pilm Co., Ltd.; assumed office as Representative Director Nov 2009 Assumed office as Chairman, Kojin Nichii Biotechnology (Beijing) Co., Ltd. Jan 2014 Assumed office as Chairman, Kojin Bio Holdings (Hong Kong) Ltd. (current) May 2014 Assumed office as Chairman, Gaojin Biotechnology (Shanghai) Co., Ltd. (current) Mar 2022 Assumed office as Director, TAKA Corporation Co., Ltd. (current) Jun 2026 Assumed office as Representative Director, Chairman, Kojin Co., Ltd. (current)
1949-05-23
Yuichi NAKAMURA
Representative Director, President, General Manager of Sales
Apr 2001 Joined Daiwa Securities Co., Ltd. Oct 2006 Joined Shinko Securities Co., Ltd. (current Mizuho Securities Co., Ltd.) Apr 2009 Joined Kojin Co., Ltd. May 2010 Assumed office as Director, Kojin Co., Ltd. Jul 2014 Assumed office as Director, Kojin Bio Holdings (Hong Kong) Ltd. (current) Oct 2014 Assumed office as Representative Director, President, Enbio Co., Ltd. (current) Jan 2016 Assumed office as Managing Director, Kojin Co., Ltd. Jun 2016 Assumed office as Director, Gaojin Biotechnology (Shanghai) Co., Ltd. (current) Jun 2018 Assumed office as Director, Ajinomoto Kojin Biotech Co., Ltd. Jun 2019 Assumed office as Director, Pilm Co., Ltd. Mar 2022 Assumed office as Director, TAKA Corporation Co., Ltd. (current) Jun 2024 Assumed office as Senior Managing Director, Kojin Co., Ltd. Jun 2026 Assumed office as Representative Director, President, Kojin Co., Ltd. (current)
1978-08-29
Hisayoshi TAIBICHI
Director, General Manager of Research
Jul 2006 Postdoctoral Researcher, Venture Business Laboratory, Nara Institute of Science and Technology May 2007 Postdoctoral Researcher, Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology Apr 2008 Joined Oncotherapy Science, Inc. Mar 2009 Joined Asylum Technology Co., Ltd. (current Oxford Instruments K.K.) Dec 2009 Joined Kojin Co., Ltd. Jan 2015 General Manager, Biology Research Department, Kojin Co., Ltd. Apr 2020 Part-time Lecturer, Kanazawa Medical University (current) Apr 2020 Executive Officer, General Manager of Research and Cell Processing, Kojin Co., Ltd. May 2021 Assumed office as Director, Gaojin Biotechnology (Shanghai) Co., Ltd. (current) Jun 2024 Assumed office as Director, Ajinomoto Kojin Biotech Co., Ltd. (current) Jun 2024 Assumed office as Director, Kojin Co., Ltd. (current)
1975-07-01
Minoru HARA
Director
Jun 1983 Registered as Certified Tax Accountant Jun 1983 Head, Hara Tax Accountant Office May 2002 Board Member, Wakatake Chuo Gakuen Wakatake Kindergarten (current) Jun 2005 Outside Audit and Supervisory Board Member, ULVAC, Inc. Feb 2008 Accounting Advisor, Kyowa Kogyo Co., Ltd. Aug 2019 Outside Audit and Supervisory Board Member, Takamura Organic Technology Co., Ltd. (current) Mar 2020 Outside Audit and Supervisory Board Member, Rentacom Life Co., Ltd. Jun 2021 Assumed office as Outside Director, Kojin Co., Ltd. (current) Oct 2022 Co-Representative Partner, Kyobashi Sogo Tax Corporation (current) Feb 2023 Outside Audit and Supervisory Board Member, Kyowa Kogyo Co., Ltd. (current) Feb 2023 Advisor, Kyobashi Branch, Tokyo Tax Accountants' Association (current)
1958-06-16
Yasuhiro MORIKANE
Director, Audit and Supervisory Committee Member
Apr 1979 Joined TOSO Co., Ltd. Apr 2007 General Manager, Accounting Department, Administration Division, TOSO Co., Ltd. Jun 2009 Assumed office as Director, General Manager, Accounting Department, Administration Division, TOSO Co., Ltd. Apr 2011 Assumed office as Director, General Manager, Administration Division, TOSO Co., Ltd. Jun 2015 Assumed office as Audit and Supervisory Board Member, TOSO Co., Ltd. Jun 2016 Assumed office as Director, Audit and Supervisory Committee Member, TOSO Co., Ltd. Jun 2020 Assumed office as Outside Audit and Supervisory Board Member, Kojin Co., Ltd. Dec 2023 Assumed office as Supervisor, Gaojin Biotechnology (Shanghai) Co., Ltd. (current) Jun 2026 Assumed office as Outside Director, Audit and Supervisory Committee Member, Kojin Co., Ltd. (current)
1956-06-24
Kazuhiro HIROSAWA
Director, Audit and Supervisory Committee Member
Apr 1992 Joined Ogawa Shinkin Bank Jan 2002 Joined Saitama Shinkin Bank Sep 2002 Joined Shinkin Securities Co., Ltd. Apr 2007 Established Hirosawa Social Insurance and Labor Consultant Office; assumed office as Head (current) May 2011 Established Total Ranger Co., Ltd.; assumed office as Representative Director (current) Oct 2013 Established With Co., Ltd.; assumed office as Director (current) Jun 2015 Assumed office as Outside Audit and Supervisory Board Member, Kojin Co., Ltd. Jun 2026 Assumed office as Outside Director, Audit and Supervisory Committee Member, Kojin Co., Ltd. (current)
1967-11-19
Hideaki UMETSU
Director, Audit and Supervisory Committee Member
Aug 2002 Joined Tsuji Hongo Tax Corporation Sep 2003 Joined Kubo Tax and Accounting Office Dec 2003 Registered as Certified Tax Accountant Aug 2005 Assumed office as Head, Umetsu Accounting Office (current) Jun 2015 Assumed office as Outside Audit and Supervisory Board Member, Kojin Co., Ltd. Jun 2026 Assumed office as Outside Director, Audit and Supervisory Committee Member, Kojin Co., Ltd. (current)
1973-03-06
Large Shareholding Reports
Gordian Capital Singapore Private Limited
2025-09-08
6.02%→7.11%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-06-23
Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2026-02-13
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2025-11-13
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2025-09-08
Large Shareholding Report
TDnet
2025-08-14
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-24
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-14
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-14
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-14
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-28
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINETAmended
2024-04-16
Amended Securities Registration Statement
EDINETAmended
2024-04-08
Amended Securities Registration Statement
EDINET
2024-03-22
Securities Registration Statement
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →